Zealand Pharma's Petrelintide Shows Double-Digit Weight Loss in Phase 2 Trial — Zealand Pharma A/S

Event summary

Phase 2 ZUPREME-1 trial data shows petrelintide achieved up to 10.7% body weight reduction vs. 1.7% for placebo at week 42.
88-98% of participants successfully escalated to maintenance dose with low discontinuation rates due to GI adverse events (1.5%).
Petrelintide improved cardiometabolic risk factors, including waist circumference (-7.9 to -10.8 cm) and hsCRP (-17 to -41%).
Phase 3 trials for chronic weight management planned to begin in H2 2026 under Zealand-Roche collaboration.

The big picture

Zealand Pharma's positive Phase 2 data for petrelintide comes as the obesity drug market expands beyond GLP-1 agonists, with amylin analogs emerging as a potential new class. The Zealand-Roche collaboration positions petrelintide to compete in a market projected to exceed $100 billion by 2030, though success will depend on demonstrating superior durability and tolerability. The Phase 3 initiation timeline suggests a potential 2029 launch, assuming smooth development.

What we're watching

Regulatory Pathway: Whether the Phase 3 trial design will satisfy global regulators for accelerated approval pathways.
Market Differentiation: How Zealand and Roche position petrelintide against GLP-1 agonists in the competitive obesity market.
Commercialization Strategy: The pace at which the companies can establish petrelintide as a first-choice therapy for chronic weight management.